Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM2 | P31350 | 4/20 | 0.70 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.70 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.70 |
| ▸ | RRM1 | P23921 | 1/20 | 0.63 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.63 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.63 |
| ▸ | CTH | P32929 | 3/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triapine SCHEMBL29370 | 0.77 | RRM2 (1.00) | RRM2NCOA3NCOA1RRM1RRM2B | |
| Triapine SCHEMBL29362841 | 0.77 | RRM2 (1.00) | RRM2NCOA3NCOA1RRM1RRM2B | |
| Triapine SCHEMBL29365763 | 0.77 | RRM2 (1.00) | RRM2NCOA3NCOA1RRM1RRM2B | |
| Triapine SCHEMBL31238438 | 0.77 | RRM2 (1.00) | RRM2NCOA3NCOA1RRM1RRM2B | |
| Triapine SCHEMBL29371 | 0.77 | RRM2 (1.00) | RRM2NCOA3NCOA1RRM1RRM2B | |
| SCHEMBL6676547 | 0.77 | RRM2 (0.73) | RRM2NCOA3NCOA1RRM1RRM2B | |
| SCHEMBL6676551 | 0.77 | RRM2 (0.73) | RRM2NCOA3NCOA1RRM1RRM2B | |
| SCHEMBL12676883 | 0.74 | RRM2 (0.50) | RRM2NCOA3NCOA1RRM1RRM2B | |
| SCHEMBL12676693 | 0.74 | RAB9A (0.43) | KDM4EPOLB | |
| SCHEMBL8683080 | 0.72 | RRM2 (0.50) | RRM2NCOA3NCOA1RRM1RRM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335726-B1 | MODIFIED PRODRUG FORMS OF AP | NANOTHERAPEUTICS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | NANOTHERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | AP3B1, AP3D1, AP3M1 | RRM2 449/4885NCOA3 696/4885NCOA1 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.